News

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy


Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.

Read more

Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board

Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board


Amsterdam, the Netherlands and London, UK – 15 November 2023 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of multiple international experts to its Scientific Advisory Board.

Read more

ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines

ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines

 

- ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need

- Series A led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company and existing investors including Origin Capital, Meltwind and O2H
Read more

Biocair Helps FibroFind Fast-Track Vital Fibrosis Drug Development

The experienced life science logistics company, Biocair, provides critical logistics support to a cutting-edge research project into drugs that can treat, and prevent, one of the world’s more serious medical conditions, fibrosis.


Biocair is supporting the innovative, UK-based contract research company, FibroFind, to deliver precious project samples from its pre-clinical research studies to pharmaceutical companies across the world. So far, Biocair has accomplished over 100 rapid, reliable sample deliveries worldwide for FibroFind.

Read more

Cambridge life Sciences is delighted to Showcase our trusted range of IVD assays at Medica

Cambridge Life Sciences is the trusted name in in vitro diagnostic assay kits and we are delighted to be showcasing them at Medica 2023 on the UK Pavilion in Hall 16.


We have 4 key product kits – Paracetamol Assay, Salicylate Assay, Endosc-Hp® Rapid Urease Test and Autozyme® autoimmune kits.


“With our products being trusted in the UK’s highly renowned NHS for over 40 years, we are seeking to find new distributors to get us known across Europe and Medica is the ideal place to meet with them.” said John Gannon, Chief Commercial Officer”.

Read more

Great Place to Work ® Institute Certifies Thermo Fisher Scientific in India for the Fifth Consecutive Year

 
~ Company also ranked amongst 100 Best Companies for Women twice in a row


Mumbai, 3rd Nov, 2023:  Thermo Fisher Scientific in India has once again been recognized with two prestigious awards, strengthening its position as a leading workplace in the country. The company has been certified as a Great Place to Work by the Great Place to Work Institute for the fifth consecutive year and ranked among the 100 Best Companies for Women in India for the second year in a row by Avtar and Seramount.

Read more

CN Bio appoints Neil Rumbelow as Director of Product Development

 
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems


Cambridge, UK, 02 November 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced it has appointed Neil Rumbelow as Director of Product Development.

Read more

INHIBRX MILESTONE TRIGGERS PAYMENT TO ARECOR UNDER LICENSE AGREEMENT

Arecor Therapeutics plc

(“Arecor” or the “Company”)


INHIBRX MILESTONE TRIGGERS PAYMENT TO ARECOR UNDER LICENSE AGREEMENT


Cambridge, UK, 2 November 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces the triggering of a milestone payment from Inhibrx Inc. (“Inhibrx”), for a novel enhanced formulation of INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™, under a license agreement entered into by the two companies in December 2020.

Read more

November eNews

Read the November eNews 

Read more

Biocair Helps FibroFind Fast-Track Vital Fibrosis Drug Development

United Kingdom, 1st November 2023 - The experienced life science logistics company, Biocair, provides critical logistics support to a cutting-edge research project into drugs that can treat, and prevent, one of the world’s more serious medical conditions, fibrosis. 

Read more

Pages